Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease

6 May 2016

Abstract excerpt

Recent years have witnessed an emergence of a new class of therapeutic agents, termed histone deacetylase 6 (HDAC6) inhibitors. HDAC6 is one isoform of a family of HDAC enzymes that catalyse the removal of functional acetyl groups from proteins. It stands out from its cousins in almost exclusively deacetylating cytoplasmic proteins, in exerting deacetylation-independent effects and in the success that has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27154743
DOI: 10.1042/cs20160084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic diseasePMID 27154743Read ↗

Histone Deacetylase 6 in Health and DiseaseSemantic proximity Read ↗

Inhibition of HDAC6 activity in kidney diseases: a new perspectiveSemantic proximity Read ↗

Interplay Between HDAC6 and Its Interacting Partners: Essential Roles in the Aggresome-Autophagy Pathway and Neurodegenerative DiseasesSemantic proximity Read ↗

Histone deacetylase 6 in cancerSemantic proximity Read ↗

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseaseSemantic proximity Read ↗

HDAC6: Tumor Progression and BeyondSemantic proximity Read ↗

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?Semantic proximity Read ↗

Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo TractabilitySemantic proximity Read ↗

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective InhibitorsSemantic proximity Read ↗

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal CancerSemantic proximity Read ↗

Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human DiseasesSemantic proximity Read ↗

HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievementsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.